These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 1520752)
1. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors. Ballarè M; Campanini M; Airoldi G; Zaccala G; Bertoncelli MC; Cornaglia G; Porzio M; Monteverde A Minerva Gastroenterol Dietol; 1992; 38(1):41-4. PubMed ID: 1520752 [TBL] [Abstract][Full Text] [Related]
2. [Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin]. Perrot JL; Guy C; Bour Guichenez G; Amigues O; Servoz J; Cambazard F Ann Dermatol Venereol; 1994; 121(11):817-9. PubMed ID: 7631993 [TBL] [Abstract][Full Text] [Related]
3. Acute cholestatic hepatitis during simvastatin administration. Ballaré M; Campanini M; Catania E; Bordin G; Zaccala G; Monteverde A Recenti Prog Med; 1991 Apr; 82(4):233-5. PubMed ID: 1857844 [TBL] [Abstract][Full Text] [Related]
4. Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors. Krasovec M; Elsner P; Burg G Dermatology; 1993; 186(4):248-52. PubMed ID: 8513188 [TBL] [Abstract][Full Text] [Related]
5. [Clinically manifest liver lesions during use of simvastatin]. Koornstra JJ; Ottervanger JP; Fehmers MC; Stricker BH Ned Tijdschr Geneeskd; 1996 Apr; 140(15):846-8. PubMed ID: 8668280 [TBL] [Abstract][Full Text] [Related]
6. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin. De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554 [TBL] [Abstract][Full Text] [Related]
7. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans]. Schmidt J; Schmitt C; Hockwin O Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817 [TBL] [Abstract][Full Text] [Related]
8. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin. England JD; Walsh JC; Stewart P; Boyd I; Rohan A; Halmagyi GM Aust N Z J Med; 1995 Aug; 25(4):374-5. PubMed ID: 8540887 [No Abstract] [Full Text] [Related]
9. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Newman A; Clutterbuck RD; Powles RL; Catovsky D; Millar JL Leuk Lymphoma; 1997 Feb; 24(5-6):533-7. PubMed ID: 9086443 [TBL] [Abstract][Full Text] [Related]
10. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. Morris MJ; Gilbert JD; Hsieh JY; Matuszewski BK; Ramjit HG; Bayne WF Biol Mass Spectrom; 1993 Jan; 22(1):1-8. PubMed ID: 8431499 [TBL] [Abstract][Full Text] [Related]
11. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Arnadottir M; Eriksson LO; Thysell H; Karkas JD Nephron; 1993; 65(3):410-3. PubMed ID: 8289991 [TBL] [Abstract][Full Text] [Related]
12. Pravastatin, simvastatin, and lovastatin for lowering serum cholesterol concentrations. Med Lett Drugs Ther; 1992 Jun; 34(872):57-8. PubMed ID: 1593973 [No Abstract] [Full Text] [Related]
13. [Effect of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, pravastatin and simvastatin, on colony formation by hematopoietic progenitor cells]. Kunitama M; Komatsu N; Miura Y Rinsho Ketsueki; 1996 Nov; 37(11):1314-7. PubMed ID: 8960668 [TBL] [Abstract][Full Text] [Related]
14. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin. Maher VM; Thompson GR Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917 [TBL] [Abstract][Full Text] [Related]
15. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Eckernäs SA; Roos BE; Kvidal P; Eriksson LO; Block GA; Neafus RP; Haigh JR Br J Clin Pharmacol; 1993 Mar; 35(3):284-9. PubMed ID: 8471404 [TBL] [Abstract][Full Text] [Related]
16. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. Pierno S; De Luca A; Tricarico D; Roselli A; Natuzzi F; Ferrannini E; Laico M; Camerino DC J Pharmacol Exp Ther; 1995 Dec; 275(3):1490-6. PubMed ID: 8531120 [TBL] [Abstract][Full Text] [Related]
17. [Myopathy caused by inhibitors of hydroxymethylglutaryl-coenzyme A reductase]. Martinez-García FA; Martín-Fernández J; Moltó JM; Villaverde R; Morales A; Fernández-Barreiro A Rev Neurol; 1997 Jun; 25(142):869-71. PubMed ID: 9244616 [TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275 [TBL] [Abstract][Full Text] [Related]
19. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia. Pappu AS; Bacon SP; Illingworth DR J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170 [TBL] [Abstract][Full Text] [Related]
20. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Germershausen JI; Hunt VM; Bostedor RG; Bailey PJ; Karkas JD; Alberts AW Biochem Biophys Res Commun; 1989 Feb; 158(3):667-75. PubMed ID: 2493245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]